Table SI. Strong and moderate barriers to the prescription of biologicals divided into 4 barrier categories

	Overall (n = 195) n (%)	Bavaria (n = 115) n (%)	Lower Saxony (n = 80) n (%)	p-value
Physicians' concerns				
No experience with biologicals	47 (24.1)	25 (21.8)	22 (27.5)	0.774
Insufficient knowledge	37 (19.0)	19 (16.5)	18 (22.6)	0.153
Insecurity with guidelines	31 (16.0)	16 (14.0)	15 (18.8)	0.506
Lack of time for treatment adjustment	51 (26.2)	28 (24.3)	23 (28.8)	0.908
Complexity of medical pre-examination	57 (29.2)	39 (34.0)	18 (22.5)	0.162
Disapproval by colleagues	19 (9.9)	11 (9.5)	8 (10.3)	0.982
Disapproval by supervisor[a]	7 (3.9)	5 (4.7)	2 (2.8)	0.747
Patients' concerns				
Patients' concerns with regard to side-effects	85 (43.6)	56 (48.7)	29 (36.3)	0.262
Patients' concerns for other reasons	80 (41.3)	50 (43.5)	30 (38.0)	0.740
External factors				
Insufficient reimbursement	93 (48.4)	59 (51.8)	34 (43.6)	0.150
Fear of regress	97 (50.0)	55 (47.8)	42 (53.2)	0.813
High costs	106 (54.6)	58 (50.9)	48 (60.0)	0.631
Previous regress claims[a]	14 (7.2)	4 (3.6)	10 (12.6)	0.076
Concerns regarding biologicals themselves				
Concerns with regard to safety	42 (21.6)	27 (23.4)	15 (18.5)	0.679
Insufficient efficiency	10 (5.1)	4 (3.5)	6 (7.5)	0.415
Inappropriate risk benefit profile	14 (7.2)	9 (7.9)	5 (6.3)	0.845
Insufficient scientific evidence with regard to efficiency and quality	7 (3.6)	3 (2.6)	4 (5.1)	0.649
Sufficiency of conventional therapy	63 (32.5)	40 (34.5)	23 (29.2)	0.548

[a]"Disapproval by supervisor" and "Previous regress claims" were not considered for calculating means of barrier strengths. (p = 0.05); missing values excluded.